Researchers from Exact Sciences Corp. and their partner the Mayo Clinic have developed and done initial testing on a DNA biomarker blood-based test to detect hepatocellular carcinoma (HCC), the most common kind of liver cancer. The company aims to meet with the FDA before year-end regarding additional clinical and regulatory steps, with a trial expected to start early next year.